Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc11.6 | Oral Communications 11: Thyroid 2 | ECE2022

A new grading system for medullary thyroid cancer

Prete Alessandro , Gambale Carla , Torregrossa Liborio , Bottici Valeria , Cappagli Virginia , Basolo Fulvio , Elisei Rossella , Matrone Antonio

Introduction: medullary thyroid carcinoma (MTC) is a neuroendocrine thyroidal cancer. World Health Organization recognizes a grading system for almost all neuroendocrine tumors; however, a shared grading system for MTC is still lacking. We performed a clinical and pathological review of 257 MTCs to evaluate which histologic features have an impact on the disease specific survival and to propose a new grading system.Method: We retrospectively reviewed cli...

ea0063p392 | Thyroid 1 | ECE2019

The presence of tall cells, even if

Matrone Antonio , Gambale Carla , Torregrossa Liborio , Valerio Laura , Molinaro Eleonora , Basolo Fulvio , Vitti Paolo , Elisei Rossella

Background: CV-PTC is often indolent with excellent long-term response, while TCV-PTC (≥50% of tall cells) have aggressive features and worse clinical behavior. Less is known about the clinical behavior of CV-PTC with tall cells <50% (TC/CV-PTC) that, so far, is considered as low risk tumor.Aim: To evaluate the histological presentation of CV-PTC, TC/CV-PTC, TCV-PTC and their clinical behavior after 6 years of follow up.M...

ea0084ps3-15-140 | Thyroid Cancer Diagnosis & Treatment | ETA2022

Basal calcitonin as guide for an early and safe thyroid surgery in RET gene carriers

Prete Alessandro , Gambale Carla , Bottici Valeria , Cappagli Virginia , Matrone Antonio , Materazzi Gabriele , Basolo Fulvio , Romei Cristina , Elisei Rossella

Introduction: Virtually all familial cases of Medullary Thyroid Carcinoma (MTC) have a RET germline mutation. Subjects harboring RET germline mutation without unaware of their condition are defined gene carriers (GC). Thyroid surgery timing is decided upon RET mutation and calcitonin levels (both basal, bCT, and stimulated, sCT). However, bCT and sCT thresholds for planning thyroid surgery have not been established, yet.Methods...

ea0049ep1414 | Thyroid (non-cancer) | ECE2017

Significant difference between the prevalence of C cell hyperplasia (CCH) in benign thyroid nodules without histological thyroiditis (HT) and in papillary/follicular thyroid cancers (PTC/FTC) at histology

Pieruzzi Letizia , Molinaro Eleonora , Agate Laura , Bottici Valeria , Torregrossa Liborio , Ugolini Clara , Basolo Fulvio , Vitti Paolo , Elisei Rossella

Background: CCH and serum hypercalcitoninemia (iperCT) can be found in benign thyroid diseases such as thyroiditis and in some cases of papillary (PTC) or follicular (FTC) thyroid microcarcinomas. The question of whether the association with these latter is related to the malignancy of the nodule is still unclear.Aim of the study: To evaluate the difference in the CCH prevalence, at histology, in a series of benign (BTN) and malignant (PTC/FTC) thyroid n...

ea0040p1 | (1) | ESEBEC2016

Genetic heterogeneity of medullary thyroid carcinoma

Romei Cristina , Ciampi Raffaele , Tacito Alessia , Casella Francesca , Ugolini Clara , Porta Mireira , Torregrossa Liborio , Basolo Fulvio , Elisei Rossella

Genetic intratumor heterogeneity has been recently demonstrated in some solid human cancers and a few years ago RET mutated and not mutated cells were described in medullary thyroid carcinoma (MTC). Nobody reported the presence of two different RET mutations.Aim of our study was to investigate the RET somatic mutation profile in primary MTC (pMTC) and in the corresponding metastatic tissues (mets).We studied pMTC and mets of 22 MTC...

ea0014oc5.4 | Thyroid basic | ECE2007

BRAFV600E mutations but not RET/PTC rearrangements are correlated with a lower expression of NIS mRNA expression in papillary thyroid cancer (PTC)

Romei Cristina , Piampiani Pamela , Faviana Pinuccia , Basolo Fulvio , Bottici Valeria , Sculli Mariangela , Berti Piero , Materazzi Gabriele , Pinchera Aldo , Elisei Rossella

Several studies have identified a relationship between oncogene activation and dedifferentiation of PTC. Mutations of RAS, RET/PTC and BRAF modulate the expression of thyroid genes. An impaired NIS expression has been demonstrated in PTCs harboring the BRAFV600E mutation.Aim of this study was to analyze BRAF and RET/PTC1-3 alterations and their influence on the expression of thyroid differentiation genes. Seventy-one PTC samples were studied. Quantitative analysis o...

ea0092op-12-03 | Oral Session 12: Emerging Insights into Thyroid Cancer Genetics | ETA2023

Different histological variants in multifocal PTC analyzed by NGS show an independent molecular origin

Ramone Teresa , Ciampi Raffaele , Romei Cristina , Casalini Roberta , Almeida Jacqueline , Minaldi Elisa , Ugolini Clara , Signorini Francesca , Basolo Fulvio , Elisei Rossella

Objective: Currently, data about the molecular profile of multifocal papillary thyroid cancer (PTC) are still controversial. The aim of this study was to fully characterize by NGS the molecular profile of different histological variants in patients affected by multifocal PTCs.Methods: for this purpose, 12 multifocal PTC patients have been studied based to the following inclusion criteria: 1) a minimum of two tumors foci per patient with at least two diff...

ea0084ps1-03-20 | Thyroid Cancer CLINICAL 1 | ETA2022

Changes in clinical status after second 131I treatment in patients with differentiated thyroid cancer (dtc) not cured with the initial treatment

Gambale Carla , Matrone Antonio , Bottaro Valeria , Prete Alessandro , Faranda Alessio , Contartese Lea , Bianchi Francesca , Torregrossa Liborio , Basolo Fulvio , Molinaro Eleonora , Elisei Rossella

Objectives: Currently 131I treatment after surgery is suggested in selected intermediate-risk and in high-risk patients with DTC. In patients with radio-avid structural disease and in those with biochemical disease a second 131I treatment could be considered. However data about the impact of the second 131I treatment on clinical status remains controversial.Methods: Clinical data of 231 DTC patients followed at the Unit o...

ea0084ps2-10-89 | Nodules & Cancer | ETA2022

Follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) showed peculiar ultrasonographic features compared to follicular variant of papillary thyroid carcinoma (FV-PTC), follicular carcinoma (FTC) and follicular adenoma (FA)

De Napoli Luigi , Matrone Antonio , Gambale Carla , Pieroni Erica , Boni Giulia , Aghababyan Aleksandr , Enrico Ambrosini Carlo , Torregrossa Liborio , Basolo Fulvio , Materazzi Gabriele , Elisei Rossella

Background: Up to 2016, NIFT-P was considered a non-invasive encapsulated follicular variant of papillary thyroid carcinoma (FV-PTC) and was reclassified and downgraded to a pre-malignant lesion. However, if these nodules have peculiar ultrasonographic features able to pre-operatively suggest their histology is still a matter of discussion. We evaluated a large series of NIFT-P, FV-PTC, FTC, and FA to characterize their ultrasonographic features.Methods:...

ea0014oc1.2 | Thyroid clinical | ECE2007

Expression gene profile may be useful for the diagnosis of thyroid malignancies

Piampiani Pamela , Romei Cristina , Cosci Barbara , Vivaldi Agnese , Ciampi Raffaele , Viola David , Bottici Valeria , Giannini Riccardo , Basolo Fulvio , Pinchera Aldo , Elisei Rossella

Although 20% of follicular neoplasms are papillary thyroid carcinoma (PTC), their cytological diagnosis is not diagnostic. A different profile of gene expression between malignant and benign thyroid tumors has been reported. Aim of this study was to identify a gene expression profile to be used in distinguishing malignant from benign thyroid neoplasms. By real-time RT-PCR we analyzed mRNA expression of 6 thyroid differentiation genes (TTF-1, PAX8, TPO, TSHr, NIS and Tg) and 5 ...